Trial Profile
GM-CSF and Ipilimumab as Therapy in Metastatic Melanoma, a Phase II Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Sargramostim (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms GIPI
- 17 Mar 2020 Status changed from active, no longer recruiting to completed.
- 05 Apr 2013 New source identified and integrated (Mayo Clinic).
- 03 Jun 2011 New trial record